New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). Click here for more information. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

The FDA Grants Accelerated Approval to Atacicept for Adults with IgAN

July 8, 2026 – This week marks another important milestone for the IgA nephropathy (IgAN) community. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to atacicept (TRUTAKNA), Vera Therapeutics’ new treatment for adults with primary IgAN who are at risk for disease progression.

The FDA’s accelerated approval program allows for earlier access to treatments that address serious conditions with unmet medical needs by using a surrogate endpoint. Defined by the FDA, a surrogate endpoint is a clinical trial endpoint used as a substitute for a direct measure of how a patient feels, functions, or survives. In this case, the surrogate endpoint is proteinuria reduction. 

IgAN is a rare kidney disease in which Immunoglobulin A (IgA) builds up in the kidney. IgA is a protein in the blood and is also part of the immune system. Excess IgA can cause inflammation in the kidney and over time, this leads to scarring in the kidney tissue. The severity of kidney disease caused by IgAN varies from person to person. As IgAN progresses, it reduces the kidneys’ ability to filter waste from the blood.

Atacicept is the first FDA-approved treatment for IgAN that targets both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which are two proteins involved in the immune response that contribute to the production of abnormal IgA. By blocking both BAFF and APRIL, atacicept is designed to address the underlying immune processes that drive the disease. 

The FDA’s approval was based on interim results from the ongoing Phase 3 ORIGIN 3 clinical trial, which showed:

  • A 46% reduction in proteinuria from baseline after 36 weeks of treatment
  • A 42% greater reduction in proteinuria compared with placebo
  • Consistent reductions in proteinuria across patient groups regardless of age, sex, region, baseline proteinuria, baseline eGFR, or use of SGLT2 inhibitors

The study also found that the atacicept was generally well tolerated, the most common side effects were infections and injection site reactions.

It is not yet known whether atacicept slows long-term kidney function decline. The ongoing Phase 3 ORIGIN 3 study will continue to evaluate this, with results expected later this year.

With today’s approval, there are now seven FDA-approved treatment options for rare, protein-spilling kidney diseases, including therapies for IgAN, focal segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G), and primary IC-MPGN.

  • TRUTAKNA (atacicept) – Approved for IgAN
  • VOYXACT (sibeprenlimab) – Approved for IgAN
  • EMPAVELI (pegcetacoplan) – Approved for C3G and primary IC-MPGN
  • FABHALTA (iptacopan) – Approved for C3G and IgAN
  • FILSPARI (sparsentan) – Approved for IgAN and FSGS
  • TARPEYO (budesonide) – Approved for IgAN
  • VANRAFIA (atrasentan) – Approved for IgAN

The growing number of approved treatment options represents remarkable progress for the rare kidney disease (RKD) community. Just a few years ago, there were no FDA-approved treatments for any rare, protein-spilling kidney disease. Today, patients living with RKD have more treatment options than ever before. 

NephCure remains committed to ensuring every person affected by rare, protein-spilling kidney disease has equitable access to the care, treatments, and support they need.

If you or a loved one has IgAN, talk with your nephrologist to determine whether atacicept or another approved treatment may be appropriate for your individual treatment plan.

Looking for expert care? Use NephCure’s Specialist Finder to locate a nephrologist with expertise in rare kidney diseases near you.

To read Vera Therapeutics’ full announcement about the FDA approval of atacicept, click here.

To learn more about IgA nephropathy and explore NephCure’s educational resources, click here.

FDA Approves Sparsentan for FSGS, Marking a Landmark Achievement for Patients Living with Rare Kidney Disease

PHILADELPHIA, PA – April 14, 2026 — Yesterday marked a historic milestone for the focal segmental glomerulosclerosis (FSGS) community. The U.S. Food and Drug Administration (FDA) has approved Travere Therapeutics’ drug sparsentan (FILSPARI) for FSGS. This is the first-ever FDA-approved treatment option for people living with FSGS, signaling a major step forward after decades without any approved, disease-specific therapies. 
 
Sparsentan is already approved for the treatment of IgA nephropathy, and the FDA’s approval expands its use to include people living with FSGS, reflecting continued progress in the development of treatments for rare kidney diseases (RKD).  
 
FSGS is a rare and progressive kidney disease. It begins in the filtering units of the kidney, the glomeruli, and causes scarring in the kidney and can ultimately lead to kidney failure. For years, patients and families have faced this disease with limited treatment options, and no therapies specifically approved for FSGS. 
 
The FDA’s approval for sparsentan was based on data from Travere Therapeutics’ Phase 3 DUPLEX study, the largest study of FSGS patients to date. In this randomized, controlled trial of 371 patients—including primary and genetic forms, as well as those considered to have refractory FSGS—sparsentan was evaluated against an active comparator treatment, irbesartan. Results, published in The New England Journal of Medicine, showed that patients treated with sparsentan achieved a statistically significant 46% reduction in proteinuria from baseline to week 108, compared to 30% for those treated with maximum labeled dose irbesartan. 

In addition, Travere’s press release shared the following: 

  • Patients without nephrotic syndrome who were treated with sparsentan experienced a 48% reduction in proteinuria, compared to 27% for those treated with irbesartan 
  • Sparsentan-treated patients without nephrotic syndrome also demonstrated a clinically meaningful benefit and preservation in eGFR. 

“Today is a powerful and long-awaited moment for the FSGS community. After decades without approved treatment options, this decision represents real progress and new hope for patients and families who have carried the weight of this disease for far too long. This progress reflects years of dedication from patients, families, researchers, physicians, regulatory partners, industry and many others across the highly collaborative rare kidney disease community who have worked tirelessly to move the science forward,” said Josh Tarnoff, NephCure chief executive officer. 
 
“This approval marks meaningful momentum for everyone living with FSGS. At NephCure, we are committed to helping patients and families understand what this means for them and to ensuring they have access to the information, support, and expert care needed to navigate drug access.” 

Sparsentan has been approved to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 

While FSGS and nephrotic syndrome may be diagnosed in conjunction, they are not the same condition. FSGS is a disease that is diagnosed through a kidney biopsy, when a characteristic pattern of scarring is seen in the kidneys. This scarring is permanent and can get worse over time. Nephrotic syndrome is a separate term that describes a patient’s condition and indicates the presence of three symptoms occurring at the same time:  

  • Proteinuria greater than 3.5 g/24h 
  • Albuminuria less than 3.0 g/dl 
  • Edema 

Nephrotic syndrome can be a symptom of severe FSGS, but not all patients with FSGS have nephrotic syndrome. Many FSGS patients often transition in and out of nephrotic syndrome episodes, depending on how their kidney disease behaves or responds to treatment. 

“There are many patients with FSGS who are at risk of losing their kidneys because our current therapeutic options are not enough. To have a new option is an incredible opportunity. I hope that sparsentan is the first of many new therapies and that someday, far fewer patients with FSGS and other glomerular diseases will go on to have kidney failure,” said Laura Mariani, M.D., M.S., NephCure Specialist, Associate Professor of Nephrology at the University of  Michigan, PARASOL Project Co-Chair, and Principal Investigator of CureGN. 

“In addition, glomerular disease is having an incredible moment, where improved understanding of disease mechanisms is combined with better clinical trial design. Some of the best elements of the way the DUPLEX study was designed make it easier to apply the results to clinical practice. The work of the PARASOL project also provides confidence that results observed in the short window of a clinical trial can give us meaningful information about future risk of kidney failure,” said Mariani.  

This approval represents a significant expansion of treatment options for people living with FSGS and reflects growing recognition of the urgent unmet need within the RKD community. It also is a testament to the strength and persistence of the FSGS community, including the individuals who participated in clinical trials such as DUPLEX and DUET, as well as long standing research studies like NEPTUNE, CureGN, and RADAR. Collaborative efforts such as the PARASOL Project, along with the contributions of researchers, advocacy organizations, and industry partners helped make this milestone possible.   

 
NephCure also recognizes Travere Therapeutics for their persistence and dedication to patients, as well as the Division of Cardiology and Nephrology at the FDA for their innovation and commitment to advancing therapies for the RKD community.  
 
While this approval allows doctors to prescribe sparsentan for FSGS, access is not automatic and may vary based on individual circumstances. Patients may encounter differences in access depending on insurance coverage, prior authorization requirements, physician familiarity with the treatment, and their individual health profile. The medication will be distributed through specialty pharmacy channels and may not be immediately available to all patients. 
 
People living with FSGS are encouraged to speak with their nephrologist to understand whether this treatment may be appropriate for them, what the approved indication includes, and how to navigate access. Now more than ever, it is critical to connect with a NephCure Specialist who understands FSGS and evolving treatment options. 
 
This moment also reflects the power of patient advocacy. The voices of the FSGS community, including those who participated in outreach efforts like NephCure’s FSGS Petition to the FDA, played an important role in advancing progress and bringing urgency to the need for new treatment options. 
 
NephCure remains committed to ensuring that this milestone translates into meaningful impact for patients by advancing access, supporting education, and continuing to drive research forward. While this approval is a major step, the work is not done. NephCure will continue to advocate for innovation and improved outcomes for all individuals affected by FSGS and other rare kidney diseases. 
 
We encourage you to join us on Monday, April 20 at 8pm ET for an informative town hall led by Drs. Kirk Campbell, Laura Mariani, and Howard Trachtman, where they will discuss what this approval means for those impacted by FSGS and answer questions from the community. To submit your questions to the doctors and register for the town hall, click here.  
 
If you or a loved one is living with FSGS, speak with your nephrologist to determine whether sparsentan or another treatment option may be right for you. 
 
To read Travere Therapeutics full press release about the FDA approval of sparsentan for FSGS, click here.  
 
 

About NephCure: 
NephCure’s mission is to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity. 

NephCure Celebrates 3rd Annual APOL1 Awareness Day on April 28th 2026

NephCure, a leading nonprofit organization fighting to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible, is proud to celebrate the third annual APOL1 Kidney Disease Awareness Day, on April 28, 2026. This day is dedicated to raising awareness of APOL1 kidney disease, which is a genetic form of kidney disease that disproportionately affects people of African ancestry. 

Apolipoprotein L1 (APOL1) kidney disease is caused by specific variants in the APOL1 gene that can led to an increased risk of developing kidney disease. These variants are believed to have originated in populations in West Africa, where they developed thousands of years ago as protection against certain parasitic diseases. 

APOL1 kidney disease disproportionately impacts individuals of African ancestry: 

  • African Americans make up 13% of the U.S. population, but account for nearly 35% of people with kidney failure in the U.S. 
  • 1 in 8 African Americans are at risk of a genetic form of kidney disease (caused by the APOL1 gene mutations). 
  • APOL1 kidney disease is particularly aggressive and currently has no FDA-approved treatments. 
  • Approximately 40% of African Americans on dialysis have kidney failure caused by APOL1. 

Because individuals who inherit certain APOL1 variants may face a higher risk of developing kidney disease, education, awareness, and advocacy are critical to enabling early detection, improving outcomes, and advancing equitable access to care. 

In honor of APOL1 Awareness Day, NephCure has launched a multi-channel awareness campaign designed to empower the nephrology community with accessible, up-to-date information on APOL1kidney disease. The initiative highlights critical resources, including genetic testing, care pathways, and emerging treatment options, to support informed decision-making and improved patient outcomes. 

Get Involved: 

NephCure invites everyone to spread awareness on social media by downloading the toolkit. The toolkit allows the public to share APOL1 kidney disease awareness graphics and patient stories on social media channels. 

For those living with APOL1 Kidney Disease, we encourage you to raise your voice and help drive meaningful change in access to care and treatment. By sharing your story, you can help drive progress in how this disease is understood and treated. This APOL1 Awareness Day, April 28, we’re unveiling a unique opportunity to connect directly with the researchers and decision-makers who are shaping the future of APOL1 care. Sign up to be the first to learn how you can get involved, click here.  

To learn more about APOL1 Kidney Disease Awareness Day, and NephCure’s APOL1 awareness efforts, please visit NephCure.org/APOL1-Awareness-Day-2026 

About NephCure: 
NephCure’s mission is to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity. 

NephCure Celebrates Kidney Month this March with Awareness Campaign

PHILADELPHIA, PA – March 1,2026 – March is National Kidney Month, and NephCure is proud to join the global movement to raise awareness about kidney health. NephCure has been squarely focused on rare, protein-spilling kidney diseases (RKD) for the last twenty-six years and is committed to advocating for the many patients and families affected by conditions such as FSGS, IgAN, MN, and other rare, protein-spilling kidney diseases. 

NephCure Leverages Kidney Month Campaign to Support New Mission 

In January 2026, NephCure announced a new mission that reflects both the extraordinary progress achieved for rare kidney disease and the organization’s vision for the next era of patient support.  

For more than 25 years, NephCure has worked alongside patients, caregivers, researchers, physicians, and industry partners to transform the rare kidney disease landscape. When the organization was founded, scientific understanding of these conditions was limited, there were no FDA-approved treatments, and virtually no therapies in development to serve the hundreds of thousands of Americans affected by rare kidney diseases. 

Today, that landscape has dramatically changed. NephCure has helped make six FDA-approved treatments possible, supported more than 60 clinical trials, and built a thriving community of over 40,000 families. 

However, scientific progress alone is not enough. 

Too many families still face delayed diagnoses, limited access to specialists, and systemic barriers that prevent timely access to care and emerging treatments. In response, NephCure has refined its focus and introduced its new mission: 
 
To ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible. 

Kidney Month Campaign Highlights 

NephCure’s Kidney Month campaign is composed of a dedicated Kidney Month landing page, email outreach and a social media campaign that not only explain their new mission but also demonstrates the meaningful steps already underway to bring that mission to life. 

The campaign includes: 

  • Opportunities for patients to share their stories through written or video submissions
  •  A social media advocacy toolkit encouraging supporters to share messages  on their own platforms 
  • Inspiring patient stories offering guidance and connection 
  • A community survey to better understand patient needs
  • Information about and registration to Rare Kidneys on the Hill Day, an advocacy event that connects patients directly with Members of Congress to advance health equity through meaningful legislation  
  • Brand education about NephCure, including the 2025 Impact Report detailing NephCure’s programs and research investments 
  • Volunteer opportunities 
  • A curated collection of educational tools designed to expand access to care 
  • Kidney Month merchandise, including hats and pins that promote grassroots awareness 

NephCure invites individuals, organizations, and advocates to help amplify the voices of those living with rare kidney diseases. By raising awareness, we can accelerate progress toward better treatment access and improved quality of life for all who are affected. 

Show your support this Kidney Month by purchasing a Kidney Month pin and sharing your advocacy on social media using our downloadable toolkit by clicking here.  

Corporate Sponsors and Partners  

Thank you to our NephCure Corporate Members who are our valued partners for Kidney Month and World Kidney Day Campaigns. Their generous support enables NephCure to develop programs, events and educational resources to pursue our mission of ensuring access to the care and treatments that offer patients the best kidney health outcome possible.  

Thank you to: Travere Therapeutics, Boehringer-Ingelheim, Novartis, Otsuka, Vertex Pharmaceuticals, Apellis Pharmaceuticals, Alexion, Amicus Therapeutics, AstraZeneca, Calliditas Therapeutics, and Vera Therapeutics. 

Additionally, NephCure is partnering with Xtrema Ceramic Cookware, and PatientsLikeMe to amplify the Kidney Month campaign across social media.  

About NephCure 

NephCure’s mission is to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity. 

Update on FDA Decision About Sparsentan for FSGS | NephCure Town Hall

Headline decoration line

Click to Watch…

The U.S. Food and Drug Administration (FDA) has been reviewing an application for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The initial date for the FDA to make a decision on this drug was January 13, 2026. On that date, the FDA issued what is called a major amendment, which means the review process will take more time. NephCure’s virtual townhall answered key questions about this decision and what it means for the FSGS community.

Visit our Youtube page

Letter to the NephCure Community: Update on FDA Decision About Sparsentan for FSGS

Dear NephCure Rare Kidney Disease Community, 

As you may know, the U.S. Food and Drug Administration (FDA) has been reviewing an application for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The initial date for the FDA to make a decision on this drug was January 13, 2026. On that date, the FDA issued what is called a major amendment, which means the review process will take more time.

The information below is intended to clarify what this change to the FDA’s review timeline means, and just as importantly, what it does not mean.

What is a Major Amendment?
A major amendment is neither an approval nor a denial from the FDA. It means that the FDA now has more time to complete its review of the study data.

It means:

  • The FDA is continuing its review of the drug and its study data.
  • The FDA will be in contact with the study sponsor (Travere Therapeutics) and may ask for additional information or have further questions.
  • The FDA issues a major amendment only when additional review time could potentially support an approval. It gives the FDA more time to fully evaluate the study data and review questions they have identified up to this point. 

A major amendment extends the Prescription Drug User Fee Act (PDUFA) decision date by three months. The new PDUFA  date for sparsentan in FSGS, or target date for the FDA to make their decision, is April 13, 2026.

The FDA may make a decision earlier than that date if they determine they have enough information to complete their review. 

You may be aware that sparsentan has already been approved by the FDA to treat IgA nephropathy (IgAN) in adults, which is another rare and progressive kidney disease that can be characterized by proteinuria. Although this means that the FDA is already familiar with sparsentan and its safety and efficacy in IgAN, it’s important to note that the approval of any drug for a distinct disease must be studied and reviewed separately. In other words, approval for IgAN does not automatically mean approval for FSGS.

What Does This Mean for You?
For individuals affected by FSGS, every step forward matters. This extension allows additional time for careful review of data and discussion around this condition – its high costs to individuals’ quality of life and overall health, future risks, and the current lack of treatments. NephCure remains optimistic about the path forward for sparsentan, and respects the FDA’s rigorous and careful review process, particularly for complex diseases like FSGS. 

At the same time, we understand that the added waiting period for this regulatory review can be difficult. Many in the FSGS community are living with uncertainty every day, and delays can feel deeply personal. We know that a great deal of disease progression can occur in a few short months for individuals living with FSGS. NephCure is committed to keeping the rare kidney disease community informed with clear updates, and we will continue to elevate the patient voice and keep the experiences, needs, and preferences of those living with FSGS at the forefront for decision-makers at the FDA.

Join the FSGS Community Town Hall
To help provide more details and answer your questions related to this update, NephCure will host a virtual FSGS Community Town Hall on Wednesday, January 21st at 7pm ET. 

The town hall will be led by NephCure Specialists Dr. Matthias Kretzler  and Howard Trachtman. 

It will focus on: 

  • Sharing more information on the drug development and FDA review process
  • Explaining how this may impact you and your family
  • Listening to our FSGS community and answering your questions 
  • Providing ways that you can make your voice heard by decision-makers

Anyone impacted by FSGS should join this important conversation. To view the FSGS Community Town Hall, click here. 

Additional resources and updates will be shared in the coming weeks to ensure the RKD community stays informed.

Sincerely, 
Josh Tarnoff and the NephCure Team

The FDA Grants Accelerated Approval to VOYXACT, a New Treatment Option for Adults with IgA Nephropathy

December 2, 2025 — Last week, another major step forward was made for the IgA nephropathy (IgAN) community. The FDA granted accelerated approval for VOYXACT (sibeprenlimab-szsi), Otsuka’s new treatment for adults with primary IgAN who are at risk for disease progression. 

The FDA’s accelerated approval program allows for earlier access to treatments that address serious conditions with unmet medical needs by using a surrogate endpoint. Defined by the FDA, a surrogate endpoint is a clinical trial endpoint used as a substitute for a direct measure of how a patient feels, functions, or survives. In this case, the surrogate endpoint is proteinuria reduction. 

IgAN is a kidney disease in which Immunoglobulin A (IgA) builds up in the kidney. IgA is a protein in the blood and is also part of the immune system. Excess IgA can cause inflammation in the kidney and over time, this leads to scarring in the kidney tissue. The severity of kidney disease caused by IgAN varies from person to person. As IgAN progresses, it reduces the kidneys’ ability to filter waste from the blood.

While VOYXACT is not the first treatment approved for IgAN, it is the first therapy that blocks a molecule called A-PRoliferation-Inducing-Ligand (APRIL). APRIL plays a role in creating harmful IgA that drives the disease process. By blocking APRIL, VOYXACT reduces levels of galactose-deficient IgA1 (Gd-IgA1), the form of IgA closely linked to IgAN.

The FDA’s approval for VOYXACT was granted based on interim data from Otsuka’s Phase 3 VISIONARY study, which showed:

  • A 51% placebo-adjusted reduction in proteinuria at 9 months
    • Patients on VOYXACT saw a 50% decrease in proteinuria compared to a 2% decrease in the placebo group.
  • Reductions were seen at 9 months of treatment among 320 participants.

Proteinuria is a widely accepted indicator of kidney health in IgAN. Lowering proteinuria is associated with slowing damage to the kidneys, which is why it is used as a surrogate marker for accelerated approval.

It is not yet known whether VOYXACT slows long-term kidney function decline. The ongoing Phase 3 VISIONARY study will evaluate this, with results expected in 2026.

With this latest approval, there are now six FDA-approved treatment options for rare kidney disease:

  • VOYXACT (sibeprenlimab-szsi) – Approved for IgAN
  • EMPAVELI (pegcetacoplan) – Approved for C3G and primary IC-MPGN
  • FABHALTA (iptacopan) – Approved for C3G and IgAN
  • FILSPARI (sparsentan) – Approved for IgAN
  • TARPEYO (budesonide) – Approved for IgAN
  • VANRAFIA (atrasentan) – Approved for IgAN

If you or a loved one has IgAN, talk with your nephrologist to determine whether VOYXACT or another treatment option may be right for you.

To read Otsuka’s full press release about the FDA approval of VOYXACT, click here.

For more information about IgA nephropathy or to explore NephCure’s educational resources, click here.

The FDA Approves EMPAVELI, New Treatment Option for C3G and Primary IC-MPGN

In a continued wave of progress for rare kidney disease (RKD) treatments, the FDA has approved the drug EMPAVELI (pegcetacoplan) for use in patients 12 and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This approval also includes individuals who have experienced disease recurrence after kidney transplant.

C3G and primary IC-MPGN are ultra-rare, progressive diseases that damage the filtering units of the kidneys and can ultimately lead to kidney failure. 

“The approval of EMPAVELI is a historic milestone for people living with C3G and primary IC-MPGN, many of whom are adolescents or young adults,” said Josh Tarnoff, NephCure CEO. “We recognize Apellis’ commitment to these patients and their families, and to the research and innovation that will bring this life-changing treatment into the hands of patients that need it most.”

What the Research Shows

The FDA’s approval of EMPAVELI is based on results from a Phase 3 clinical trial called VALIANT, which looked at how well the treatment worked in people with C3G or primary IC-MPGN.

The study found that patients who received EMPAVELI experienced:

  • A 68% reduction in proteinuria, a key sign of disease activity
  • Stabilization of kidney function, helping to slow disease progression
  • Significant reduction in C3 deposits in the kidneys, with 71% of patients showing no remaining deposits on follow-up testing

What This Means for the RKD Community

With this approval, EMPAVELI becomes an additional option for patients and families navigating life with C3G or primary IC-MPGN. It follows the FDA’s March 2025 approval of FABHALTA for adults with C3G and continues the encouraging trend toward increased treatment options for people with rare kidney diseases.

There are now five FDA-approved treatment options for rare kidney disease:

  • EMPAVELI (pegcetacoplan) – Approved for C3G and Primary IC-MPGN
  • FABHALTA (iptacopan) – Approved for C3G and IgAN
  • FILSPARI (sparsentan) – Approved for IgAN
  • TARPEYO (budesonide) – Approved for IgAN
  • VANRAFIA (atrasentan) – Approved for IgAN

NephCure remains dedicated to advancing education, support, and advocacy for individuals affected by C3G and other RKDs. The organization encourages patients and families to speak with their healthcare providers to determine whether EMPAVELI or any other available treatment may be appropriate based on individual needs.

To read Apellis’ full press release on EMPAVELI’s approval, click here.

For more information on C3G, IC-MPGN, and available resources, visit NephCure.org.

Advancing Pediatric Kidney Disease Research: Building on the July 2023 SGLT2i Workshop

In July 2023, a landmark workshop brought together clinicians, researchers, patient advocates, and industry stakeholders to discuss the significant need for pediatric-specific studies in chronic kidney disease (CKD), with specific  focus on extrapolation of adult study data with SGLT2 inhibitors (SGLT2i) for potential application to the pediatric kidney disease population. This collaborative effort was driven by a shared understanding: while SGLT2 inhibitors have demonstrated clear benefit in adult populations with glomerular diseases, much remains unknown about their safety and efficacy in children.

As a direct result of this workshop, there has been notable momentum among pharmaceutical companies toward initiating pediatric studies involving these agents. Several sponsors are now actively working to develop clinical trial programs targeting pediatric populations, with specific attention to children living with glomerular diseases and those affected by congenital anomalies of the kidney and urinary tract (CAKUT). This forward movement marks an important step in bridging the treatment gap for pediatric patients and ensuring equitable access to potentially life-changing therapies.

Below is the summary paragraph that reflects the focus and consensus from the July 2023 workshop:

A workshop in July 2023 addressed the need for and feasibility of a randomized clinical trial testing the efficacy of SGLT2i in pediatric patients with CKD. Children with glomerular diseases are similar to adults. However, there are significant knowledge gaps in understanding the mechanism of disease progression and response to treatment in children with congenital anomalies of the kidney and urinary tract (CAKUT). There was a consensus that both groups of children need to be studied. A manuscript is in preparation summarizing the workshop proceedings.

NephCure is committed to supporting this ongoing work and continues to advocate for the inclusion of pediatric patients in all areas of rare kidney disease research and treatment development. 

NephCure Celebrates Second Annual APOL1 Kidney Disease Awareness Day on April 29, 2025

NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney diseases, is proud to announce the second annual APOL1 Kidney Disease Awareness Day, taking place on April 29, 2025. This day is dedicated to raising national awareness of APOL1 kidney disease, which is a genetic form of kidney disease that disproportionately affects people of African ancestry.

APOL1 kidney disease is caused by specific changes in the APOL1 gene, which can lead to an increased risk of developing kidney disease. People who inherit certain APOL1 gene variants may be more likely to develop kidney disease, making education, awareness, and advocacy around this condition critical for early intervention and equitable care.

To honor this important day, NephCure invites everyone to participate in the following awareness opportunities:

Join the Virtual Town Hall on April 29 at 7PM ET
NephCure will host a free, live virtual APOL1 Awareness Day Town Hall event featuring powerful perspectives and expert insights from leading voices in the kidney and health equity space, including:

  • Dr. Keisha Gibson, MD, MPH – A pediatric nephrologist from UNC Chapel Hill.
  • Corynne Corbett – Representing Black Health Matters.
  • Barbara Harrison, MS, CGC – A clinical genetic counselor from Harvard University.

Spread Awareness on Social Media
Download the toolkit and share NephCure’s APOL1 kidney disease awareness graphics and patient stories on your social media channels, don’t forget to tag @NephCure.

Fast Facts About APOL1 Kidney Disease:

  • African Americans make up 13% of the U.S. population, but account for nearly 35% of people with kidney failure in the U.S.
  • 1 in 8 African Americans is at risk of a genetic form of kidney disease (caused by the APOL1 gene mutations).
  • APOL1 kidney disease is particularly aggressive and currently has no FDA-approved treatments.
  • Approximately 40% of African Americans on dialysis have kidney failure caused by APOL1.

NephCure’s APOL1 Awareness Day efforts would not be possible without the generous support of its sponsors, Vertex Pharmaceuticals, AstraZeneca, and Maze Therapeutics.

To register for the Town Hall on April 29th and learn more about APOL1 awareness efforts, click here.

About NephCure:
NephCure’s mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity.

The FDA Grants Accelerated Approval to Vanrafia, New Treatment Option for Adults with IgA Nephropathy

A major step forward has been made for the IgA Nephropathy (IgAN) community. Last week, the FDA granted accelerated approval to Vanrafia (atrasentan), Novartis’ therapy, for adults with primary IgAN at risk of rapid disease progression. This approval brings new hope to those affected by this progressive, rare kidney disease.

As background, the FDA’s accelerated approval program allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need. 

IgA Nephropathy (IgAN) is a kidney disease in which Immunoglobulin A (IgA) builds up in the kidney. IgA is a protein in the blood and is also part of the immune system. Excess IgA can cause inflammation in the kidney and over time, this leads to scarring in the kidney tissue. The severity of kidney disease caused by IgAN varies from person to person. As IgAN progresses, it reduces the kidneys’ ability to filter waste from the blood.

Approval was granted based on interim results from Novartis’ Phase 3 ALIGN trial, which demonstrated a 36.1% reduction in proteinuria compared to placebo. Reductions were seen as early as Week 6 and sustained through Week 36. Vanrafia was also shown to have a favorable safety profile, with no new safety signals observed. Ongoing data from the ALIGN study will evaluate whether Vanrafia slows kidney function decline long-term, with final results expected in 2026.

With this latest announcement, there are now four FDA-approved therapies for IgAN — a major shift from just a few years ago:

  • FABHALTA (iptacopan) – Approved for C3G and IgAN
  • FILSPARI (sparsentan) – Approved for IgAN
  • TARPEYO (budesonide) – Approved for IgAN
  • VANRAFIA (atrasentan) – Approved for IgAN

These treatment options, each with different mechanisms of action, allow patients and their care teams to take a more personalized approach to managing this disease.

NephCure remains committed to supporting the IgAN community through continued education, research, and advocacy. While this is an exciting moment, we know the work is far from over. Our focus now turns to ensuring timely, affordable, and equitable access to these therapies for all who need them.

If you or a loved one has IgAN, we encourage you to speak with your doctor to determine which treatment may be right for you.

To read Novartis’ full press release about Vanrafia’s FDA approval, click here.

For more information on IgA Nephropathy, click here. To view and read the available resources about IgAN, please visit NephCure.org.

The FDA Approves FABHALTA, First Treatment Option for Adults with C3G

A historic milestone has been reached for the rare kidney disease (RKD) community — the FDA has approved the drug FABHALTA as the first-ever treatment option for adults with C3 glomerulopathy (C3G). This long-awaited approval brings new hope to patients and families affected by this devastating disease.

C3G is an ultra-rare, debilitating kidney disease that damages the glomeruli (the filtering units in the kidneys that help remove toxins from the blood) which can ultimately lead to kidney failure. Until now, there were no approved targeted treatment options available for C3G. 

“This approval marks a significant step forward in our collective goal to improve the outcomes of those affected by rare kidney diseases. For the first time, the C3G community has a therapy approved and designed specifically for their condition. This comes on the heels of groundbreaking advancements in IgAN, which underscores the current exciting new era of innovation in RKD treatments,” Josh Tarnoff, NephCure’s CEO said. 

FABHALTA’s approval for FABHALTA in C3G is based off Novartis’ Phase 3 study, APPEAR-C3G, which evaluated the efficacy and safety of the drug and demonstrated reduction in proteinuria, which was seen as early as 14 days. 

This marks the third FDA approval, in the U.S., for FABHALTA and its second within the Novartis’ kidney disease portfolio in less than a year. In August 2024, the drug received accelerated approval for IgA Nephropathy (IgAN). 

A New Era of Kidney Care

With this latest breakthrough, there are now four FDA-approved therapies for rare kidney disease:

  • FABHALTA (iptacopan) – Approved for C3G and IgAN
  • FILSPARI (sparsentan) – Approved for IgAN
  • TARPEYO (budesonide) – Approved for IgAN

This approval marks an important advancement, but our work is far from over. NephCure remains committed to advancing research, advocacy, and patient education to further improve treatment options and outcomes for those with C3G and other rare kidney diseases. With more than 60 clinical trials in the RKD space, we anticipate even more new treatments to be approved in the near future. 

Now, the focus shifts to ensuring timely and equitable access to these new and better treatments for all patients.

If you or a loved one has C3G, we encourage you to speak with your doctor to determine if FABHALTA may be an appropriate treatment option for you. 

To read Novartis’ press release about FABHALTA’s approval for C3G, click here.

For more information on C3G and available resources, please visit NephCure.org.